» Articles » PMID: 18541744

Cardiomyocyte Overexpression of Neuronal Nitric Oxide Synthase Delays Transition Toward Heart Failure in Response to Pressure Overload by Preserving Calcium Cycling

Abstract

Background: Defects in cardiomyocyte Ca(2+) cycling are a signature feature of heart failure (HF) that occurs in response to sustained hemodynamic overload, and they largely account for contractile dysfunction. Neuronal nitric oxide synthase (NOS1) influences myocyte excitation-contraction coupling through modulation of Ca(2+) cycling, but the potential relevance of this in HF is unknown.

Methods And Results: We generated a transgenic mouse with conditional, cardiomyocyte-specific NOS1 overexpression (double-transgenic [DT]) and studied cardiac remodeling, myocardial Ca(2+) handling, and contractility in DT and control mice subjected to transverse aortic constriction (TAC). After TAC, control mice developed eccentric hypertrophy with evolution toward HF as revealed by a significantly reduced fractional shortening. In contrast, DT mice developed a greater increase in wall thickness (P<0.0001 versus control+TAC) and less left ventricular dilatation than control+TAC mice (P<0.0001 for both end-systolic and end-diastolic dimensions). Thus, DT mice displayed concentric hypertrophy with fully preserved fractional shortening (43.7+/-0.6% versus 30.3+/-2.6% in control+TAC mice, P<0.05). Isolated cardiomyocytes from DT+TAC mice had greater shortening, intracellular Ca(2+) transients, and sarcoplasmic reticulum Ca(2+) load (P<0.05 versus control+TAC for all parameters). These effects could be explained, at least in part, through modulation of phospholamban phosphorylation status.

Conclusions: Cardiomyocyte NOS1 may be a useful target against cardiac deterioration during chronic pressure-overload-induced HF through modulation of calcium cycling.

Citing Articles

Regulation of nitric oxide generation and consumption.

Abu-Soud H, Camp O, Ramadoss J, Chatzicharalampous C, Kofinas G, Kofinas J Int J Biol Sci. 2025; 21(3):1097-1109.

PMID: 39897032 PMC: 11781162. DOI: 10.7150/ijbs.105016.


Regulatory effects of resveratrol on nitric oxide signaling in cardiovascular diseases.

Abolfazli S, Karav S, Johnston T, Sahebkar A Pharmacol Rep. 2025; .

PMID: 39832074 DOI: 10.1007/s43440-025-00694-w.


RyR2 and Calcium Release in Heart Failure.

Benitah J, Perrier R, Mercadier J, Pereira L, Gomez A Front Physiol. 2021; 12:734210.

PMID: 34690808 PMC: 8533677. DOI: 10.3389/fphys.2021.734210.


Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload.

Nakao M, Shimizu I, Katsuumi G, Yoshida Y, Suda M, Hayashi Y Sci Rep. 2021; 11(1):18384.

PMID: 34526601 PMC: 8443662. DOI: 10.1038/s41598-021-97787-2.


Genetic Deletion of NOD1 Prevents Cardiac Ca Mishandling Induced by Experimental Chronic Kidney Disease.

Gil-Fernandez M, Navarro-Garcia J, Val-Blasco A, Gonzalez-Lafuente L, Martinez J, Rueda A Int J Mol Sci. 2020; 21(22).

PMID: 33238586 PMC: 7700567. DOI: 10.3390/ijms21228868.